{"id":"bempedoic-acid-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated uric acid levels (transient)"},{"rate":null,"effect":"Gout flares"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bempedoic acid is a uricosuric agent that works upstream in the purine metabolism pathway by inhibiting xanthine oxidase through an indirect mechanism involving AMPK activation. It reduces serum uric acid levels by decreasing uric acid production, making it useful for chronic gout management and hyperuricemia in patients who cannot tolerate or respond to conventional xanthine oxidase inhibitors.","oneSentence":"Bempedoic acid inhibits AMPK-activated protein kinase to reduce uric acid production and lower serum uric acid levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:00.909Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic gout management and hyperuricemia"},{"name":"Gout prophylaxis in patients intolerant to or inadequately controlled by conventional urate-lowering therapy"}]},"trialDetails":[{"nctId":"NCT06450366","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-08","conditions":"Hypercholesterolemia","enrollment":301},{"nctId":"NCT07268625","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-12-09","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT05687071","phase":"PHASE3","title":"A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2023-02-27","conditions":"Hyper-low-density Lipoprotein (LDL) Cholesterolemia","enrollment":130},{"nctId":"NCT07235189","phase":"PHASE1","title":"A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-28","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT07374861","phase":"","title":"Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-11-04","conditions":"Hypercholesterolemia","enrollment":1500},{"nctId":"NCT07201545","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-07","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT07282821","phase":"PHASE2","title":"Bempedoic Acid Therapy for Polycystic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Kenneth Hallows","startDate":"2026-02-01","conditions":"ADPKD (Autosomal Dominant Polycystic Kidney Disease)","enrollment":120},{"nctId":"NCT07182383","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-09-29","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT06925100","phase":"PHASE4","title":"A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-04-01","conditions":"Primary Hypercholesterolemia or Mixed Hyperlipidemia","enrollment":180},{"nctId":"NCT07239414","phase":"PHASE3","title":"Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability","status":"NOT_YET_RECRUITING","sponsor":"Sohaib Ashraf","startDate":"2025-11-10","conditions":"Cardiovascular","enrollment":690},{"nctId":"NCT06742853","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-12-20","conditions":"Dyslipidemia","enrollment":81},{"nctId":"NCT07170852","phase":"PHASE1","title":"Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-05-21","conditions":"Hypercholesterolaemia","enrollment":32},{"nctId":"NCT05694260","phase":"PHASE2","title":"A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2023-01-12","conditions":"Hypercholesterolemia","enrollment":31},{"nctId":"NCT06923956","phase":"PHASE1","title":"Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2024-12-04","conditions":"Hypercholesterolaemia, Mixed Dyslipidaemia, Cardiovascular Diseases","enrollment":14},{"nctId":"NCT06021951","phase":"PHASE4","title":"Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2023-08-04","conditions":"Healthy Lactating Women","enrollment":16},{"nctId":"NCT06280976","phase":"PHASE4","title":"Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2024-03-01","conditions":"Coronary Artery Disease, Atherosclerosis, Heart Attack","enrollment":""},{"nctId":"NCT05683340","phase":"PHASE3","title":"A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2023-02-13","conditions":"Hyper-low-density Lipoprotein (LDL) Cholesterolemia","enrollment":96},{"nctId":"NCT06780410","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2024-12-20","conditions":"Primary Hyperlipidemia","enrollment":240},{"nctId":"NCT04784442","phase":"PHASE2","title":"A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2021-03-24","conditions":"Hypercholesterolemia","enrollment":188},{"nctId":"NCT02993406","phase":"PHASE3","title":"Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-12-22","conditions":"Cardiovascular Diseases, Statin Adverse Reaction","enrollment":13970},{"nctId":"NCT05263778","phase":"PHASE4","title":"Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study","status":"UNKNOWN","sponsor":"Kaiser Permanente","startDate":"2022-03","conditions":"Cardiovascular Diseases, NSTEMI, STEMI","enrollment":500},{"nctId":"NCT03067441","phase":"PHASE3","title":"Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-02-03","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Disease","enrollment":1462},{"nctId":"NCT02666664","phase":"PHASE3","title":"Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-01-21","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases","enrollment":2230},{"nctId":"NCT03001076","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-11-29","conditions":"Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction","enrollment":269},{"nctId":"NCT02991118","phase":"PHASE3","title":"Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-11-18","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Disease","enrollment":779},{"nctId":"NCT03531905","phase":"PHASE2","title":"Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2018-05-09","conditions":"Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia","enrollment":242},{"nctId":"NCT03337308","phase":"PHASE3","title":"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-10-23","conditions":"Hyperlipidemias","enrollment":382},{"nctId":"NCT03193047","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-04-07","conditions":"Hypercholesterolemia","enrollment":59},{"nctId":"NCT02988115","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-11-16","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction","enrollment":345},{"nctId":"NCT02659397","phase":"PHASE2","title":"A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2015-12","conditions":"Hyperlipidemia","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bempedoic Acid Tablet","genericName":"Bempedoic Acid Tablet","companyName":"Gan & Lee Pharmaceuticals.","companyId":"gan-lee-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bempedoic acid inhibits AMPK-activated protein kinase to reduce uric acid production and lower serum uric acid levels. Used for Chronic gout management and hyperuricemia, Gout prophylaxis in patients intolerant to or inadequately controlled by conventional urate-lowering therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}